Clinical trials: Sudan Ebola Virus Vaccines
Ebola
A Study in Tanzania of a New Vaccine Against Two Types of Ebola
An open label, first in human, non-randomised, dose escalation, single centre, phase Ib clinical trial
- Trial name
- NCT05301504
- Testing
- ChAdOx1 biEBOV
- Where
- Tanzania
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Sudan Ebola Virus Vaccines
Solidarity/Tokomeza Ebola Trial
The TokomezaPlus Ebola trial is a phase I/II double blind randomised clinical trial designed to assess the safety and immunogenicity of candidate SUDV vaccines in Uganda during the inter outbreak period.
- Trial name
- TOKOMEZA (NCT05909358)
- Testing
- CAd3, ChAdox1, rVSV-SUDV
- Volunteers
- 2,121 people, healthy volunteers welcome
- Sponsor
- Makerere University
Ebola
A Study of a New Vaccine Against Two Types of Ebola
An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species…
- Trial name
- NCT05079750
- Testing
- ChAdOx1 biEBOV
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Sudan Virus Disease
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.
- Trial name
- NCT07565090
- Testing
- rVSVΔG-SUDV-GP
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Ebola Sudan Virus Disease
Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults
- Trial name
- NCT06036602
- Testing
- cAD3-Sudan Ebolavirus Vaccine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Ebola Virus
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
RV 508 was a Phase I, open-label, dose-escalation study to examine the safety, tolerability and immunogenicity of an investigational Ebola vaccine in healthy adults.
- Trial name
- NCT04041570
- Testing
- cAd3-EBO S vaccine
- Where
- Uganda
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Sudan Virus Disease
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
- Trial name
- NCT06803342
- Testing
- cAd3-Sudan Vaccine
- Where
- 4 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Ebola Sudan Virus Disease
Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
- Trial name
- NCT05724472
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative